Guideline for the pharmacological treatment of hypertension in adults: summary
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
World Health Organization
Abstract
Description
1 p.
This summary presents the key recommendations from the WHO Guideline for the pharmacological treatment of hypertension in adults, developed to support the prevention of cardiovascular disease associated with elevated blood pressure. It highlights the global burden of hypertension and outlines the evidence-based recommendations for initiating and managing pharmacological treatment in adults. The publication summarizes guidance on blood pressure thresholds for starting antihypertensive therapy, indications for treatment in individuals with cardiovascular disease or other high-risk conditions, and recommendations regarding laboratory testing and cardiovascular risk assessment before treatment when these do not delay care. The document also summarizes recommendations on the selection of first-line antihypertensive drug classes, the use of combination therapy, blood pressure treatment targets, follow-up intervals during treatment, and the role of trained nonphysician health workers in hypertension management under appropriate supervision. For each recommendation, the summary indicates the strength of the recommendation and the certainty of the supporting evidence, providing a concise overview of the guideline to facilitate its implementation in clinical practice and health systems
This summary presents the key recommendations from the WHO Guideline for the pharmacological treatment of hypertension in adults, developed to support the prevention of cardiovascular disease associated with elevated blood pressure. It highlights the global burden of hypertension and outlines the evidence-based recommendations for initiating and managing pharmacological treatment in adults. The publication summarizes guidance on blood pressure thresholds for starting antihypertensive therapy, indications for treatment in individuals with cardiovascular disease or other high-risk conditions, and recommendations regarding laboratory testing and cardiovascular risk assessment before treatment when these do not delay care. The document also summarizes recommendations on the selection of first-line antihypertensive drug classes, the use of combination therapy, blood pressure treatment targets, follow-up intervals during treatment, and the role of trained nonphysician health workers in hypertension management under appropriate supervision. For each recommendation, the summary indicates the strength of the recommendation and the certainty of the supporting evidence, providing a concise overview of the guideline to facilitate its implementation in clinical practice and health systems